Regeneron Pharmaceuticals 10K 2011 Annual report | REGN Filing

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: abbreviated, abrasion, Absent, accomplished, ACR, adjustedin, advisory, advocacy, affiliate, Alnylam, aminotransferase, analyze, analyzing, anatomic, andAnatomic, andARCALYST, andequipment, andpreclinical, andSafety, answer, answered, approvalsof, aPreventativeStudy, ARCALYST®and, ARCALYST®for, ARCALYST®net, ARCALYST®supplemental, arterial, ascertained, aspartate, assignment, AST, AStock, atorvastatin, Avastin®in, Avastin®with, benchmark, berestricted, biosimilar, blended, borrowing, branch, breakdown, broader, BRVO, byNew, calculatingnet, CATT, causeinjury, chain, channel, chargeback, China, Chugai, Citibank, clinicaldata, CMS, collaborationagreement, conclusion, consecutive, COntrolledPhase, corneal, Corner, corrupt, creatine, CTN, customary, declaration, decomposition, deficit, dehydration, Department, deploy, deployed, Dermatologic, destination, detachment, detrimental, device, diarrhea, diminish, disproportional, distortion, dysfunction, educate, education, effectivenessto, effectsin, ELYEA, entail, entireVelociSuiteTM, eosinophilic, exacerbate, extraordinary, EYLEA, EYLEA®and, EYLEA®between, EYLEA®collaboration, EYLEA®development, EYLEA®for, EYLEA®in, EYLEA®Injection, EYLEA®must, EYLEA®of, EYLEA®outside, EYLEA®over, EYLEA®PRN, EYLEA®through, EYLEA®to, Fargo, feature, fewest, forecasting, freight, fundamental, fusion, Gastrointestinal, gathered, GeneralAssessmentLimitingInfiLtration, Goldman, gouty, guided, HealthCareled, heFH, hepato, idiopathic, immunology, incumbent, indenture, inDME, infrastructure, inherentin, injunctive, Inspector, instance, interdependent, intrusion, invoice, irritation, Italy, itsVelociGene®technology, jeopardize, juvenile, Kabushiki, Kaisha, leak, Liberty, licenseagreement, limitedand, lipid, literature, liver, lowest, lt, Lucentis®for, mandated, manually, Marc, Master, mayfall, mayshare, mCRC, merit, methotrexate, mildly, mitigating, mix, MOBILITY, monoclonalantibody, Morgan, MTX, multinational, negligible, network, neutropenia, neutropenic, nonclinical, notable, notification, ofRepeated, ofSafetyUtilizingRilonacept, OIG, onan, orphan, OS, ourVelociGene®technology, ourVelociMab®platform, ourVelocImmune®license, ourvelocimouse®technology, path, patientswere, patientsweredosed, paymentto, PDT, PDUFA, penetration, permanent, PFS, phosphokinase, photocoagulation, Photodynamic, plc, PREventionStudy, Priority, privacy, processalso, procure, progression, properly, RA, reclassified, redeem, referenced, refractory, relief, reputation, resalable, rescinded, retreatment, returnsmay, RNAi, sarilumab, satisfactory, Score, Seiyaku, settled, settlement, shipment, short, SIGHT, significantlyfaster, slightly, Smyth, specialty, standalone, Stanley, step, sterile, stipulate, strict, strike, subscribe, Suisse, superior, surrender, switch, switched, switching, takeover, tear, theNew, thrombotic, timeframe, toDME, trend, trialofAvastin, Trustee, ULN, unanimously, unanticipated, uncollectible, underperform, unexpected, unique, unmarketable, unobtainable, unprofitable, unwind, UPSURGE, User, VA, veinOcclusion, verteporfin, VIBRANT, vigorously, VISTA, VIVID, vulnerable, warehousing, warrant, Weled, Wemay, widespread, withcommercializing, withdrawn, withheld, withholding, ZALTRAP, ZALTRAP®Agreement, ZALTRAP®and, ZALTRAP®arm, ZALTRAP®collaboration, ZALTRAP®for, ZALTRAP®in, ZALTRAP®oncology, ZALTRAP®sale, ZALTRAP®to

Removed: advancing, American, assistance, attaining, attest, auditing, binding, bore, break, captioned, conclude, confidence, deferral, deposit, discussed, distributor, docetaxel, extinguishment, farther, formulated, Housing, induced, location, main, Maine, matured, motivated, negotiate, Nineteen, NSAID, occasion, occupy, operation, profitably, purified, ranibizumab, realization, refuse, regularly, remediate, repaid, represented, resolution, retrospectively, subordinated, sue, unqualified, VelociSuite, VINCI

Regeneron Pharmaceuticals (REGN) 10-K2011 FY Annual report

Content analysis